Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385639610> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4385639610 abstract "<h3>Background</h3> This study aimed to demonstrate the potential of Activated Leukocyte Cell Adhesion Molecule (ALCAM), hemopexin, and peroxiredoxin (PRDX) 6 as urine biomarkers for systemic lupus erythematosus (SLE). <h3>Methods</h3> We collected urine samples from 138 patients with SLE from Ajou Lupus Cohort and 39 healthy controls (HC). The concentrations of urine biomarker levels were analyzed by enzyme-linked immunosorbent assay kits specific for ALCAM, hemopexin and PRDX 6, respectively, according to the manufacturer’s protocols. Receiver operating characteristic (ROC) curve analysis was performed to evaluate diagnostic utility and Pearson’s correlation analysis was conducted to assess the relationships among the disease activity and urine biomarkers. <h3>Results</h3> Patients with SLE showed a 5.7-fold increase in urinary ALCAM levels compared to HCs (6,760.5 pg/ml vs. 1,192.6 pg/ml, p < 0.001). In urinary hemopexin and PRDX6, the average levels were also significantly higher in patients with SLE compared to HCs (hemopexin, 649.8 ng/ml vs. 202 ng/ml, p < 0.001; PRDX6, 0.78 ng/ml vs. 0.17 ng/ml, p = 0.003). ALCAM, hemopexin, and PRDX6 showed more significant diagnostic value, especially for lupus nephritis (LN), and the area under the receiver operating characteristic curve for LN was 0.850 for ALCAM (95% CI, 0.778–0.921), 0.781 for hemopexin (95% CI, 0.695–0.867), and 0.714 for salivary S100A8 (95% CI, 0.617–0.812). In correlation analysis, all were significantly associated with anti-double stranded DNA (ALCAM, r = 0.350, p < 0.001; hemopexin, r = 0.346, p < 0.001; PRDX6, r = 0.191, p = 0.026) and SLEDAI (ALCAM, r = 0.526, p < 0.001; hemopexin, r = 0.479, p < 0.001; PRDX6, r = 0.262, p = 0.002). <h3>Conclusions</h3> Urinary ALCAM, hemopexin and PRDX 6 were highly expressed patients with SLE compared to HCs. Thus, we suggest that urinary ALCAM, hemopexin and PRDX 6 can be potential biomarkers for SLE, especially valuable in the diagnosis of LN." @default.
- W4385639610 created "2023-08-08" @default.
- W4385639610 creator A5028863423 @default.
- W4385639610 creator A5036841412 @default.
- W4385639610 creator A5064212873 @default.
- W4385639610 creator A5079752492 @default.
- W4385639610 creator A5083253699 @default.
- W4385639610 creator A5086477416 @default.
- W4385639610 date "2023-07-01" @default.
- W4385639610 modified "2023-10-07" @default.
- W4385639610 title "LSO-016 Activated leukocyte cell adhesion molecule, hemopexin, and peroxiredoxin 6 as a potential urine biomarker for Korean patients with systemic lupus erythematosus" @default.
- W4385639610 doi "https://doi.org/10.1136/lupus-2023-kcr.57" @default.
- W4385639610 hasPublicationYear "2023" @default.
- W4385639610 type Work @default.
- W4385639610 citedByCount "0" @default.
- W4385639610 crossrefType "proceedings-article" @default.
- W4385639610 hasAuthorship W4385639610A5028863423 @default.
- W4385639610 hasAuthorship W4385639610A5036841412 @default.
- W4385639610 hasAuthorship W4385639610A5064212873 @default.
- W4385639610 hasAuthorship W4385639610A5079752492 @default.
- W4385639610 hasAuthorship W4385639610A5083253699 @default.
- W4385639610 hasAuthorship W4385639610A5086477416 @default.
- W4385639610 hasBestOaLocation W43856396101 @default.
- W4385639610 hasConcept C126322002 @default.
- W4385639610 hasConcept C16224149 @default.
- W4385639610 hasConcept C181199279 @default.
- W4385639610 hasConcept C185592680 @default.
- W4385639610 hasConcept C203014093 @default.
- W4385639610 hasConcept C2776217839 @default.
- W4385639610 hasConcept C2776474381 @default.
- W4385639610 hasConcept C2776912625 @default.
- W4385639610 hasConcept C2779134260 @default.
- W4385639610 hasConcept C2779912601 @default.
- W4385639610 hasConcept C2780026642 @default.
- W4385639610 hasConcept C2780456743 @default.
- W4385639610 hasConcept C2781197716 @default.
- W4385639610 hasConcept C55493867 @default.
- W4385639610 hasConcept C58471807 @default.
- W4385639610 hasConcept C71924100 @default.
- W4385639610 hasConcept C90924648 @default.
- W4385639610 hasConceptScore W4385639610C126322002 @default.
- W4385639610 hasConceptScore W4385639610C16224149 @default.
- W4385639610 hasConceptScore W4385639610C181199279 @default.
- W4385639610 hasConceptScore W4385639610C185592680 @default.
- W4385639610 hasConceptScore W4385639610C203014093 @default.
- W4385639610 hasConceptScore W4385639610C2776217839 @default.
- W4385639610 hasConceptScore W4385639610C2776474381 @default.
- W4385639610 hasConceptScore W4385639610C2776912625 @default.
- W4385639610 hasConceptScore W4385639610C2779134260 @default.
- W4385639610 hasConceptScore W4385639610C2779912601 @default.
- W4385639610 hasConceptScore W4385639610C2780026642 @default.
- W4385639610 hasConceptScore W4385639610C2780456743 @default.
- W4385639610 hasConceptScore W4385639610C2781197716 @default.
- W4385639610 hasConceptScore W4385639610C55493867 @default.
- W4385639610 hasConceptScore W4385639610C58471807 @default.
- W4385639610 hasConceptScore W4385639610C71924100 @default.
- W4385639610 hasConceptScore W4385639610C90924648 @default.
- W4385639610 hasLocation W43856396101 @default.
- W4385639610 hasOpenAccess W4385639610 @default.
- W4385639610 hasPrimaryLocation W43856396101 @default.
- W4385639610 hasRelatedWork W2098134050 @default.
- W4385639610 hasRelatedWork W2121244867 @default.
- W4385639610 hasRelatedWork W2158944380 @default.
- W4385639610 hasRelatedWork W2177092523 @default.
- W4385639610 hasRelatedWork W2364717911 @default.
- W4385639610 hasRelatedWork W2776803289 @default.
- W4385639610 hasRelatedWork W2778847013 @default.
- W4385639610 hasRelatedWork W2951958669 @default.
- W4385639610 hasRelatedWork W3166910253 @default.
- W4385639610 hasRelatedWork W3214891379 @default.
- W4385639610 isParatext "false" @default.
- W4385639610 isRetracted "false" @default.
- W4385639610 workType "article" @default.